AI Article Synopsis
- Immunotherapy with avelumab has transformed treatment for metastatic Merkel cell carcinoma (MCC), showing a 57% overall response rate in a study of 14 patients.
- Among the patients, 29% experienced complete responses, while another 29% had partial responses, especially those with single metastatic sites (83% effective).
- However, the treatment was less effective in patients with bone metastases, and factors like PD1-L expression and MCPyV positivity didn’t show a clear link to treatment responses.
Article Abstract
The arrival of immunotherapy has revolutioned the management of patients with metastatic Merkel cell carcinoma (MCC). We conducted an observational, retrospective study of 14 cases treated with avelumab. The response rate was 57%: complete response was reached in 29% of patients, and partial responses in 29%. The drug proved effective in 83% (5/6) of the patients with a single metastatic site. However, the disease progressed in 75% (3/4) of the patients with bone metastases. PD1-L expression, MCC polyomavirus (MCPyV) positivity, and an impaired neutrophil-to-lypmhocyte ratio (NLR) could not be associated with responses to the therapy. Avelumab is an effective and safe drug for the management of advanced MCC, and its effectiveness appears to be impacted by the number and location of metastases.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ad.2024.10.017 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!